TRI & Rho sign strategic partnership

Rho partners with TRI to provide centralized and risk-based quality management technology to their clients   Research Triangle Park, NC –  January 13, 2020 –  Rho, a full-service contract research organization (CRO) focused on bringing new products to market through a full range of product development services, announced today that it has partnered with Triumph Research Intelligence (TRI), a…

Read More

The MCC / TRI / Covance RBQM Interview

In this free podcast, Keith Dorricott from the MCC interviews Duncan Hall, CEO TRI, and Kristin Stallcup, Senior Director Covance, about all things Risk-Based Quality Management.  In this fascinating hour-long interview, they cover a wide range of topics, including KRIs, QTLs, evolving technology, the Big Data challenge and measuring success. Split into eight easy-to-listen-to sections, Keith explores the issues…

Read More

CEO Blog

CBI RBM 2019 Reflections Part 3 of 3 – Predictions for 2020 Reflecting on RBQM in 2019, and not just at the CBI conference, I am struck by how the RBQM conversations I’m having are turning quickly from “why” to “how”.  In 2020 we’ll see a much greater focus on implementation and the ‘operationalizing’ of RBQM and the rise…

Read More

COO’s Blog

January 2020 ICH E6 R3 – what next? At the end of 2019, the ICH Management Committee endorsed the business plan and scope for ICH E6 R3.  A complete re-write of E6 is being proposed, focusing on two areas: Appendix 1 – Interventional Trials; and Appendix 2 – Non-Interventional Trials. The draft technical document for Appendix 1 is expected…

Read More

FDA RBM Q&A Guidance for Industry

In March 2019 the FDA released their RBM Q&A Guidance for Industry. If you haven’t read it yet, the link is below, it makes for some interesting reading. The focus of this guidance is to provide further clarification and suggestions on how best to implement risk based approaches to monitoring. Interestingly the guidance focuses very heavily on the risk…

Read More

The R2 story – what is it, why it’s needed & why now?

Lots of people don’t understand what R2 is and why it’s needed. And unless you understand the fundamental reasons for its creation and adoption, it’s easy to dismiss it as ‘just more bureaucracy’.  But it isn’t.  It’s much more important than that, and here’s the reasons why. The way clinical trials are conducted has changed dramatically over the last…

Read More

TRI raises multi-million growth funding

TRI raises multi-million growth funding from Octopus Investments to expand its Risk-Based Monitoring platform for clinical trials 15th October 2018, LONDON, UK – TRI, a leading global provider of Risk-Based Monitoring (RBM) solutions for clinical trials, has completed a growth capital fundraise to accelerate development of its core technology platform, OPRA and expand its international presence. Founded in 2014,…

Read More

R2 survey results June 2018

Only 12% of companies reporting R2 readiness In June this year we conducted an industry survey on ICH E6 (R2) readiness, and had over 100 responses.  Only 12 % said they have completed their readiness programs.  Even more surprising, 27% of respondents said they haven’t even started yet. Given the adoption of R2 by EMA, FDA and Health Canada…

Read More

The Current State of ICH E6 Revision 2

In November 2017, one of the EMA’s Inspectors, Sophia Mylona, reiterated the importance of Revision 2 (R2) to the attendees at the 5th Global QA conference in Edinburgh, Scotland. Her message surprised the crowd. Not because ICH E6 (R2) is something new. On the contrary, this revision was finalized in November 2016 and put into effect by the EMA…

Read More

The maturing of RBM implementation

As we at TRI continue to engage with industry on RBM implementation, I am pleased with the observations that we are currently making across a range of CRO and Pharma companies. Rolling back the clock 18-24 months and most of the discussions we were having with customers and prospects were about risk detection, data visualisation and stats models. For…

Read More

Top 5 Challenges to ICH E6 Rev 2 Compliance

  Let’s look at the intent and purpose of the revision … The revised Addendum is proposed to modernize ICH E6 and enable implementation of innovative approaches to clinical trial design, conduct and management that will better ensure subject protection and data quality. This is a significant and positive step, but we will only realize the benefits if we…

Read More

Setting Your Own Standards for ICH E6 Rev 2 Implementation

  The “eagerly awaited” revision to ICH E6 is going to provide a clear message about the expectation for how a clinical trial is conducted in today’s world compared to the world of the mid 1990’s when the first version was adopted by the three ICH regions. ICH E6 is by definition a guideline and therefore provides guidance, i.e….

Read More

ICH E6 Revision 2 – What Does It Mean In Practical Terms?

Nowadays we all use multiple electronic systems in clinical trials. Consequently, we need SOPs in place to define/control how these are developed, used, accessed and secured to ensure of the integrity of the data we produce.   We’ve been doing corrective and preventive actions (CAPA) for years but Revision 2 emphasizes the need to analyse the “root-cause”…

Read More

ICH E6 Revision 2 – “Begin With The End In Mind”

  Regulators will soon require sponsors and CROs to demonstrate that they have effectively anticipated, managed and mitigated risk during the course of each study.   Identifying and then setting your end point as the target is the most likely way to achieve success.  We have to know where we want to end up in order to plan and…

Read More

Capability Maturity Model for Quality Management

What is a Capability Maturity Model? A capability maturity model (CMM) is a simple way to express an organisation’s capability in a defined area against a number of parameters. The traditional model offers five levels of maturity, typically defined as 1 – Initial, 2 – Managed, 3 – Defined, 4 – Managed, 5 – Optimized, as seen in the…

Read More